EMA: Q&A on biphasic MR products [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2012-03-07 04:52 (4814 d 01:22 ago) – Posting: # 8223
Views: 23,009

Dear ElMaestro!

❝ I can follow the logic, …


Me too. Like it.

❝ … although I could be a little afraid that the innovator industry as a means of brand protection could start building IP protection around the cut-offs (or other). It would be tremendously effective if granted.


Can be very tough. Early partial AUCs are always highly variable. No scaling for EMA… See this one (slides 51–56). Besides the CV, have a look at the PEs of the two studies of slide 54. All formulations got approval as hybrids (MR vs. IR + clinical studies). Interchangeability: ¡nada!

❝ What's your own take on this?


I make my living from it. :-D
Joking aside I like that some clinical reasoning seems to come back. Or I’m just getting old (1980s-style: steady state to reduce variability, active metabolite if longer half-live than parent, music of the Talking Heads, Laurie Anderson’s performances, etc.).


Meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee,
April 13, 2010
Midha KK and G McKay
Use of Partial Area Under the Curve for BE Assessment of Products with Complex PK Profiles; a View Point
slides 1–58
RA Lionberger
PK Profile Comparison for Modified Release Products
slides 59-85
BM Davit
Use of Partial AUC: Case Studies and BE Approaches
slides 86-177

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
68 visitors (0 registered, 68 guests [including 4 identified bots]).
Forum time: 07:14 CEST (Europe/Vienna)

If you shut your door to all errors
truth will be shut out.    Rabindranath Tagore

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5